nach oben

Erschienen in:

26.03.2024 | Original Communication

Efgartigimod in the treatment of Guillain–Barré syndrome

verfasst von: Huiqiu Zhang, Jing Ma, Yingna Feng, Hui Ma, Dan Liu, Xiaomin Pang, Xueli Chang, Rongjuan Zhao, Juan Wang, Junhong Guo, Wei Zhang

Erschienen in: Journal of Neurology | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Guillain–Barré Syndrome (GBS) is caused by immunoglobulin G (IgG) autoantibodies. Efgartigimod, a human IgG antibody Fc fragment that acts as a natural ligand for the FcRn, can increase IgG degradation, which thus may be a promising therapeutic drug for GBS.

Case presentation

The two patients presented with postinfectious and acute flaccid paralysis. On admission, they were bedridden. Nerve conduction studies indicated peripheral neuropathy. GBS was suspected and they are treated with two doses of efgartigimod (10 mg/kg) within 5 days. Their muscle strength improved gradually and 4 weeks after the initial dose, they could walk independently. Following the first dose, Patient 1 complaint of muscle soreness, which subsided the next morning. Patient 2 was intubated due to respiratory failure the day after the initial dose, and did not report other adverse effects.

Discussion

In GBS patients, two doses of efgartigimod (10 mg/kg) were effective in rapidly improving muscle strength, with a satisfactory safety profile. The findings suggest a potential role for efgartigimod in modifying the disease process in GBS patients.

Conclusion

Efgartigimod seems effective and safe in the treatment of GBS. This study indicates the potential role of efgartigimod as a novel treatment option for GBS. Well-designed clinical trials should be conducted.

Nur mit Berechtigung zugänglich

Shahrizaila N, Lehmann HC, Kuwabara S (2021) Guillain-Barré syndrome. Lancet (London, England) 397(10280):1214–1228. https://doi.org/10.1016/s0140-6736(21)00517-1CrossRefPubMed

Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K et al (2004) Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA 101(31):11404–11409. https://doi.org/10.1073/pnas.0402391101CrossRefPubMedPubMedCentral

Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC (1995) Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 38(2):218–224. https://doi.org/10.1002/ana.410380214CrossRefPubMed

Koga M, Takahashi M, Yokoyama K, Kanda T (2015) Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants. J Neurol 262(8):1954–1960. https://doi.org/10.1007/s00415-015-7806-4CrossRefPubMed

(1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma exchange/sandoglobulin Guillain-Barré syndrome trial group. Lancet (London, England). 349(9047):225–30.

Donofrio PD, Berger A, Brannagan TH 3rd, Bromberg MB, Howard JF, Latov N et al (2009) Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 40(5):890–900. https://doi.org/10.1002/mus.21433CrossRefPubMed

Patel A, Lynch F, Shepherd SA (2020) Newer immunotherapies for the treatment of acute neuromuscular disease in the critical care unit. Curr Treat Options Neurol 22(3):7. https://doi.org/10.1007/s11940-020-0616-8CrossRefPubMed

Burakgazi AZ (2019) Immunoglobulin treatment in neuromuscular medicine. J Clin Neuromuscul Dis 20(4):182–193. https://doi.org/10.1097/cnd.0000000000000235CrossRefPubMed

Szczeklik W, Wawrzycka K, Włudarczyk A, Sega A, Nowak I, Seczyńska B et al (2013) Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensiv Ther 45(1):7–13. https://doi.org/10.5603/ait.2013.0002CrossRef

10.

Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY et al (2021) Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 20(4):275–283. https://doi.org/10.1016/s1474-4422(20)30494-4CrossRefPubMed

11.

Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715–725. https://doi.org/10.1038/nri2155CrossRefPubMed

12.

Newland AC, Sánchez-González B, Rejtő L, Egyed M, Romanyuk N, Godar M et al (2020) Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol 95(2):178–187. https://doi.org/10.1002/ajh.25680CrossRefPubMed

13.

Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E et al (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Investig 128(10):4372–4386. https://doi.org/10.1172/jci97911CrossRefPubMedPubMedCentral

14.

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A et al (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92(23):e2661–e2673. https://doi.org/10.1212/wnl.0000000000007600CrossRefPubMedPubMedCentral

15.

Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526–536. https://doi.org/10.1016/s1474-4422(21)00159-9CrossRefPubMed

16.

Suzuki S, Uzawa A, Murai H (2022) Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective. Expert Rev Clin Immunol 18(12):1207–1215. https://doi.org/10.1080/1744666x.2022.2136167CrossRefPubMed

17.

Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H et al (2023) Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (London, England) 402(10413):1648–1659. https://doi.org/10.1016/s0140-6736(23)01460-5CrossRefPubMed

18.

Goebeler M, Bata-Csörgő Z, De Simone C, Didona B, Remenyik E, Reznichenko N et al (2022) Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol 186(3):429–439. https://doi.org/10.1111/bjd.20782CrossRefPubMed

19.

Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K et al (2018) Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 17(6):519–529. https://doi.org/10.1016/s1474-4422(18)30114-5CrossRefPubMed

20.

Breiner A, Barnett C, Bril V (2014) INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve 50(2):164–169. https://doi.org/10.1002/mus.24207CrossRefPubMed

21.

Ren K, Yang A, Lu J, Zhao D, Bai M, Ding J et al (2022) Association between serum low-density neutrophils and acute-onset and recurrent Guillain-Barré syndrome. Brain Behav 12(1):e2456. https://doi.org/10.1002/brb3.2456CrossRefPubMed

22.

Kleyweg RP, van der Meché FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 14(11):1103–1109. https://doi.org/10.1002/mus.880141111CrossRefPubMed

23.

Vanhoutte EK, Draak TH, Gorson KC, van Nes SI, Hoeijmakers JG, Van der Pol WL et al (2015) Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison. J Peripher Nerv Syst: JPNS 20(3):289–295. https://doi.org/10.1111/jns.12118CrossRefPubMed

24.

Blumberg LJ, Humphries JE, Jones SD, Pearce LB, Holgate R, Hearn A et al (2019) Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv 5(12):eaax9586. https://doi.org/10.1126/sciadv.aax9586CrossRefPubMedPubMedCentral

25.

Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS (2019) The neonatal Fc receptor (FcRn): a misnomer? Front Immunol 10:1540. https://doi.org/10.3389/fimmu.2019.01540CrossRefPubMedPubMedCentral

26.

Jaffry M, Menkes DL, Shaikh A, Mandava K, Kothari O, Jaffry K et al (2023) Neonatal Fc receptor inhibitor therapeutics in neuromuscular disease. J Clin Neuromuscul Dis 24(4):188–198. https://doi.org/10.1097/cnd.0000000000000451CrossRefPubMed

27.

Hughes RA, Swan AV, van Doorn PA (2014) Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014(9):Cd002063. https://doi.org/10.1002/14651858.CD002063.pub6CrossRefPubMedPubMedCentral

28.

Zhao F, Wang J, Zhang J, Pang X, Huang S, Chang X et al (2021) Pain in acute motor axonal neuropathy. Muscle Nerve 64(6):739–743. https://doi.org/10.1002/mus.27414CrossRefPubMed

29.

Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT (2014) Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol 5:682. https://doi.org/10.3389/fimmu.2014.00682CrossRefPubMed

30.

Fokkink WR, Walgaard C, Kuitwaard K, Tio-Gillen AP, van Doorn PA, Jacobs BC (2017) Association of albumin levels with outcome in intravenous immunoglobulin-treated Guillain-Barré syndrome. JAMA Neurol 74(2):189–196. https://doi.org/10.1001/jamaneurol.2016.4480CrossRefPubMed

Titel: Efgartigimod in the treatment of Guillain–Barré syndrome
verfasst von: Huiqiu Zhang
Jing Ma
Yingna Feng
Hui Ma
Dan Liu
Xiaomin Pang
Xueli Chang
Rongjuan Zhao
Juan Wang
Junhong Guo
Wei Zhang
Publikationsdatum: 26.03.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 6/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-024-12321-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Case presentation

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2024

Outcome predictors of post-COVID conditions in the European Academy of Neurology COVID-19 registry

Sir Henry Dale (1875–1968)

Pallidal deep brain stimulation for patients with myoclonus-dystonia without SGCE mutations

Symptoms and signs did not predict outcome after surgery: a prospective study of 143 patients with idiopathic normal pressure hydrocephalus

Clinical treatment of cryptococcal meningitis: an evidence-based review on the emerging clinical data